臨床検査54巻4号

2010年04月発行

今月の主題 広義のアポリポ蛋白 各論 〈臨床検査への応用の可能性〉

比較的新しいアポリポ蛋白―apoL, apoM

著者： 岡本康幸¹

所属機関： ¹奈良県立医科大学附属病院中央臨床検査部

ページ範囲：P.369 - P.374

　アポリポ蛋白L(apoL)とM(apoM)は，いずれも比較的新しく同定された主にHDLに含まれるアポリポ蛋白である．血漿apoL(apoL-Ⅰ)はトリグリセリドと強い正の相関を示すが，動脈硬化性疾患との関連は不明である．apoL-Ⅰを含むHDLの亜分画はトリパノソーマを融解する作用を示す．一方，apoMは，コレステロールの逆転送系においてpreβ-HDLの形成を促進し，動脈硬化に対し防御的に作用していると考えられている．コレステロールとの相関が強いが，糖尿病患者などで低下する例が報告されている．いずれもユニークな機能をもつアポリポ蛋白であり，今後新しい臨床検査項目となる可能性も十分考えられる．

参考文献

1) Duchateau PN, Pullinger CR, Orellana RE, et al：Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. J Biol Chem　272：25576-25582, 1997

2) Xu Ning, Dahlbäck B：A novel human apolipoprotein(apoM). J Biol Chem　274：31286-31290, 1999

3) Page NM, Butlin DJ, Lomthaisong K, et al：The human apolipoprotein L gene cluster：identification, classification, and sites of distribution. Genomics　74：71-78, 2001

4) Duchateau PN, Pullinger CR, Cho MH, et al：Apolipoprotein L gene family：tissue-specific expression, splicing, promoter regions；discovery of a new gene. J Lipid Res　42：620-630, 2001

5) Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, et al：Apolipoprotein L-Ⅰ is the trypanosome lytic factor of human serum. Nature　422：83-87, 2003

6) Duchateau PN, Movsesyan I, Yamashita S, et al：Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects. J Lipid Res　41：1231-1236, 2000

7) Albert TS, Duchateau PN, Deeb SS, et al：Apolipoprotein L-Ⅰ is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL. J Lipid Res　46：469-474, 2005

8) Li Q, Fan P, Bai H, et al：Distribution and effect of apoL-Ⅰ genotype on plasma lipid and apolipoprotein levels in Chinese normolipidemic and endogenous hypertriglyceridemic subjects. Clin Chim Acta　403：152-155, 2009

9) Mowry BJ, Holmans PA, Pulver AE, et al：Multicenter linkage study of schizophrenia loci on chromosome 22q. Mol Psychiatry　9：784-795, 2004

10) Mimmack ML, Ryan M, Baba H, et al：Gene expression analysis in schizophrenia：reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci USA　99：4680-4685, 2002

11) Takahashi S, Cui Y, Han Y, et al：Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia. Schizophr Res　104：153-164, 2008

12) Christoffersen C, Nielsen LB, Axler O, et al：Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res　47：1833-1843, 2006

13) Richter S, Shih DQ, Pearson ER, et al：Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1α. Haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes　52：2989-2995, 2003

14) Nielsen LB, Christoffersen C, Ahnström J, et al：ApoM：gene regulation and effects on HDL metabolism. Trends Endocrinol Metab　20：66-71, 2009

15) Wolfrum C, Poy MN, Stoffel M：Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med　11：418-422, 2005

16) Christoffersen C, Jauhiainen M, Moser M, et al：Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem　283：1839-1847, 2008

17) Axler O, Ahnström J, Dahlbäck B：An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res　48：1772-1780, 2007

18) Jiang J, Zhang X, Wu C, et al：Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases. Lipids Health Dis　7：25, 2008

19) Ahnström J, Axler O, Jauhiainen M, et al：Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res　49：1912-1917, 2008

20) Cervin C, Axler O, Holmkvist J, et al：An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med, 2009［Epub ahead of print］

21) Plomgaard P, Dullaart RP, de Vries R, et al：Apolipoprotein M predicts pre-β-HDL formation：studies in type 2 diabetic and nondiabetic subjects. J Intern Med　266：258-269, 2009

22) Dullaart RP, Plomgaard P, de Vries R, et al：Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. Clin Chim Acta　406：129-133, 2009

23) Feingold KR, Shigenaga JK, Chui LG, et al：Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis　199：19-26, 2008

24) Wu X, Niu N, Brismar K, et al：Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes. Clin Biochem　42：17-21, 2009

25) Su W, Jiao G, Yang C, et al：Evaluation of apolipoprotein M as a biomarker of coronary artery disease. Clin Biochem　42：365-370, 2009